Angelini Pharma, Cureverse enter exclusive global option agreement to develop & commercialize innovative brain health asset, CV-01
Overview
Angelini Pharma, part of the privately owned Angelini Industries, and Cureverse Inc., an early-stage research and development company, announced that they entered into an exclusive global option agreement for the development and commercialization of Cureverse’s innovative brain health asset CV-01.
Terms of the Agreement
- Under the terms of the agreement, Angelini Pharma will lead all the development efforts for CV-01 and, following an initial option period, will have the right to obtain the global exclusive development and commercialization license for the compound, outside of the Republic of Korea, China, Hong Kong, Macau and Taiwan.
- CV-01 is a novel and innovative investigational compound that activates protective pathways regulated by the nuclear factor erythroid 2-related factor 2 (Nrf2) and has a strong potential to be a medication with disease-modifying properties across a range of brain health disorders, including epilepsy.
- CV-01 is an investigational compound currently undergoing a phase 1 clinical trial in the Republic of Korea and is being developed by Cureverse for Alzheimer’s disease.
For Cureverse
Cureverse will receive an upfront payment and will also be eligible to receive additional payments upon pre-defined development and commercial milestones of up to approx. US$ 360 million, as well as tiered royalties on post-approval net sales.
Words from the CEO: Angelini Pharma
- Our strategic collaboration with Cureverse further strengthens Angelini Pharma’s position as an emerging leader in brain health” said Jacopo Andreose, chief executive officer of Angelini Pharma.
- Neurological conditions such as epilepsy are among leading causes of disease burden worldwide. While significant progress has been achieved in the past 15 years, many people living with epilepsy are still unable to reach seizure control despite combination treatment of several anti-seizure medications. Through the development of CV-01 and potentially other compounds, we aim to provide much-needed solutions for people living with brain health conditions across the world.
Words from the CEO: Cureverse Inc.
- Our research has unveiled the remarkable potential of CV-01 to transform the landscape of brain health, from epilepsy to Alzheimer’s and Parkinson’s disease,” said Sung Jin Cho, chief executive officer at Cureverse Inc.
- We are truly delighted to be partnering with Angelini Pharma on this journey. Their deep therapeutic expertise and commitment to brain health perfectly align with our vision. Together, we are not just developing a treatment—we are paving the way for a future where patients with neurological conditions have access to truly life-changing therapies.
Therapeutic Area of Focus: Brain
- Brain health as a therapeutic area includes both neurological and mental health conditions.
- Brain health is defined by the World Health Organization as a state of brain functioning across cognitive, sensory, social-emotional, behavioural and motor domains, allowing a person to realize their full potential over the course of their life, irrespective of the presence or absence of disorders.
About Brain Health
- Brain health represents an urgent global health priority. An estimated 179 million Europeans are living with brain health conditions[vi] and more than 18% of all health loss around the world is associated with brain conditions.
- Additionally, brain health conditions are responsible for considerable individual, economic and societal impact, including loss of independence, reduced productivity, strained relationships, increased risk of suicide as well as high healthcare costs.
- There is an urgent need to raise awareness, and reduce stigma, prejudice and discrimination, to ensure that brain health is valued, promoted and protected for all.
About the Disease: Epilepsy
- Epilepsy is one of the most widespread neurological diseases in the world, affecting globally approximately 50 million people of all ages.
- In Europe, up to six million people are estimated to be living with this disease.
- Epilepsy can have multiple potential causes, including structural, metabolic, genetic and other factors, though approximately half of cases worldwide do not have a known cause.
Complications with Epilepsy
- The complications associated with epilepsy are severe, with a risk of premature mortality up to three times higher than the general population.
- The recurrent seizures associated with this condition also have wide-ranging effects on a person’s broader physical and mental health, education and employment opportunities and other quality of life factors.
To Improve Quality of Life
Treatments are available to help reduce seizures and improve quality of life, however approximately 40% of people living with epilepsy are still uncontrolled despite the treatment with two anti-seizure medications.
